Celine Verstuyft
Overview
Explore the profile of Celine Verstuyft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robert F, Benchenouf F, Ha M, Cuomo A, Ottaviani M, Surbier M, et al.
JHEP Rep
. 2025 Feb;
7(3):101297.
PMID: 39980753
Background & Aims: Hepatopulmonary syndrome (HPS) results from portal hypertension, with or without cirrhosis, and is marked by pulmonary vascular dilations leading to severe hypoxemia. Although placental growth factor (PlGF)...
2.
Verstuyft C, Dewolf D, Blin O, Florentin V, Mesnard L, Chaumette B, et al.
Therapie
. 2025 Jan;
80(1):103-112.
PMID: 39788802
4P medicine (personalized, preventive, predictive, and participatory) is experiencing a remarkable rise, and pharmacogenetics is an essential part of it. However, several obstacles are hindering its deployment. This round table...
3.
Verstuyft C, Dewolf D, Blin O, Florentin V, Mesnard L, Chaumette B, et al.
Therapie
. 2024 Dec;
80(1):93-102.
PMID: 39710540
No abstract available.
4.
Lebreton L, Boyer J, Lafay-Chebassier C, Hennart B, Baklouti S, Cunat S, et al.
Clin Pharmacol Ther
. 2024 Nov;
117(2):387-397.
PMID: 39584620
Mavacamten, the first drug in the class of β-cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in...
5.
Derobertmasure A, Toh L, Verstuyft C, Lukic S, De Sousa Carvalho C, Couronne R, et al.
Br J Clin Pharmacol
. 2024 Oct;
PMID: 39473131
Aims: Therapeutic drug monitoring for astronauts faces limitations in conventional blood sampling and sample management onboard the international space station. Here, we explore the feasibility of dried blood spot (DBS)...
6.
Chappell K, Colle R, El Asmar K, Gressier F, Bouligand J, Trabado S, et al.
Mol Psychiatry
. 2024 Oct;
PMID: 39462036
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was...
7.
Konecki C, Francou B, Chappell K, Augey L, Beaudonnet G, Cauquil C, et al.
Eur J Neurol
. 2024 Sep;
31(12):e16461.
PMID: 39230471
Background And Purpose: Small-fiber neuropathy (SFN) affects only unmyelinated and thin myelinated fibers. It may be caused by amyloidogenic mutations of the transthyretin (TTR) gene, but not all TTR gene...
8.
Tang J, Munoz T, Jolivet I, Chappell K, Choucha W, Colle R, et al.
Encephale
. 2024 Jul;
50(5):583-584.
PMID: 38971648
No abstract available.
9.
Hart X, Grunder G, Ansermot N, Conca A, Corruble E, Crettol S, et al.
World J Biol Psychiatry
. 2024 Jun;
25(9):451-536.
PMID: 38913780
Background: For psychotic disorders (i.e. schizophrenia), pharmacotherapy plays a key role in controlling acute and long-term symptoms. To find the optimal individual dose and dosage strategy, specialised tools are used....
10.
Joly C, Desjardins D, Porcher R, Pere H, Bruneau T, Zhang Q, et al.
Front Immunol
. 2023 Dec;
14:1250214.
PMID: 38077399
Background: The clinical outcome of COVID-19 pneumonia is highly variable. Few biological predictive factors have been identified. Genetic and immunological studies suggest that type 1 interferons (IFN) are essential to...